RxDoctor Payments Data

Melody Cotter, APRN

Psychiatric/Mental Health · Fredericksburg, VANPI 1447320650

Payments from drug & device makers

$2,317in general payments, 2019–2025

Across 26 payments — averaging $89.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$901
  • AbbVie$434
  • Otsuka America Pharmaceutical, Inc.$371
  • Neurocrine Biosciences, Inc.$241
  • E.r. Squibb & Sons, L.L.C.$137
  • Vanda Pharmaceuticals Inc.$125
  • plus $107 from 1 others

What the payments were for

  • Food & beverage$2,26898%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,317 in reported general payments places this provider in the 80th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$14,712
Medicare patients
64
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate32$252,128
Invega SustennaPaliperidone Palmitate52$179,087
Abilify MaintenaAripiprazole53$143,095
VraylarCariprazine Hcl77$118,522
CaplytaLumateperone Tosylate42$73,103
RexultiBrexpiprazole13$19,937
Aripiprazole148$17,445
Lurasidone Hcl55$16,458
Venlafaxine Hcl ErVenlafaxine Hcl85$6,060
Mirtazapine166$3,767
Divalproex Sodium63$3,662
Risperidone151$2,728
Buspirone Hcl229$2,459
Oxcarbazepine80$2,457
Sertraline Hcl185$2,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$241$252,12832 claims
Johnson & JohnsonInvega Sustenna$107$179,08752 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$371$163,03266 claims
AbbVieVraylar$434$118,52277 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$901$73,10342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →